DARA Biosciences Inc (NASDAQ:DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the second quarter ended June 30, 2015, after the close of the market on Wednesday, August 12, 2015.

The Company will host a conference call for investors on Thursday, August 13, 2015, at 09:00 a.m. Eastern Time. To listen to the live call, individuals can access the webcast at the investor relations portion of the Company’s website at http://ir.darabio.com/overview. Please log on to the website at least 15 minutes early to register, download and install any necessary audio software. For those who cannot listen to the live broadcast, replays will be available shortly after the call on the DARA BioSciences website.  (Original Source)

Shares of Dara Biosciences closed last Friday at $0.82. DARA has a 1-year high of $1.43 and a 1-year low of $0.67. The stock’s 50-day moving average is $0.87 and its 200-day moving average is $0.83.

On the ratings front, H.C. Wainwright analyst Reni Benjamin reiterated a Buy rating on DARA, with a price target of $2, in a report issued on May 15. The current price target implies an upside of 143.9% from current levels. According to TipRanks.com, Benjamin has a total average return of -1.1%, a 39.3% success rate, and is ranked #2965 out of 3728 analysts.

DARA Biosciences Inc is a specialty pharmaceutical company focused on the commercialization of oncology treatment and supportive care pharmaceutical products. Its products include Gelclair, Oravig and Soltamox.